Krystal Biotech (KRYS) Set to Post Quarterly Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is expected to be releasing its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Krystal Biotech to post earnings of $1.79 per share and revenue of $125.77 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. On average, analysts expect Krystal Biotech to post $7.33 EPS for the current fiscal year and $8.78 EPS for the next fiscal year.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $332.29 on Friday. Krystal Biotech has a one year low of $184.02 and a one year high of $382.54. The company’s 50-day moving average is $337.46 and its 200 day moving average is $308.68. The company has a market capitalization of $9.84 billion, a price-to-earnings ratio of 40.67 and a beta of 0.50.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 13.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Citigroup reaffirmed a “buy” rating on shares of Krystal Biotech in a report on Thursday, October 15th. Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a report on Friday, August 14th. They set an “outperform” rating and a $400.00 price target on the stock. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group started coverage on shares of Krystal Biotech in a research report on Thursday, September 24th. They set a “buy” rating and a $441.00 price target for the company. Finally, Weiss Ratings upgraded shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $377.20.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.